Upgrade to SI Premium - Free Trial

Aprea Therapeutics (APRE)

0.66 +0.01 (1.54%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology June 22, 2026 8:30 AM - StreetInsider Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Grissinger Michael June 17, 2026 7:10 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Gruia Gabriela June 17, 2026 7:08 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Peters Richard June 17, 2026 7:07 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: HENNEMAN JOHN B III June 17, 2026 7:06 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: BIZZARI JEAN-PIERRE June 17, 2026 7:05 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Duey Marc June 17, 2026 7:04 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Pamukcu Rifat June 17, 2026 7:03 PM - SEC Filing Form 4 Aprea Therapeutics, Inc. For: Jun 16 Filed by: Seizinger Bernd R. June 17, 2026 7:03 PM - SEC Filing Form 8-K Aprea Therapeutics, Inc. For: Jun 16 June 17, 2026 4:16 PM - SEC Filing Aprea Therapeutics shares Phase 1 data for cancer drug APR-1051 June 1, 2026 8:00 AM - StreetInsider Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors June 1, 2026 8:00 AM - StreetInsider Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Vestal Point Capital, LP May 15, 2026 5:04 PM - SEC Filing Form 424B7 Aprea Therapeutics, Inc. May 15, 2026 4:38 PM - SEC Filing Aprea (APRE) PT Lowered to $6 at Wedbush May 13, 2026 4:10 PM - StreetInsider Aprea Therapeutics (APRE) Misses Q1 EPS by 22c May 13, 2026 6:51 AM - StreetInsider Form 10-Q Aprea Therapeutics, Inc. For: Mar 31 May 13, 2026 6:46 AM - SEC Filing Form 8-K Aprea Therapeutics, Inc. For: May 13 May 13, 2026 6:36 AM - SEC Filing Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update May 13, 2026 6:30 AM - Globe NewsWire Oppenheimer Starts Aprea (APRE) at Outperform May 7, 2026 6:06 AM - StreetInsider Form ARS Aprea Therapeutics, Inc. For: Dec 31 April 30, 2026 6:45 AM - SEC Filing Form DEFA14A Aprea Therapeutics, Inc. April 30, 2026 6:40 AM - SEC Filing Form DEF 14A Aprea Therapeutics, Inc. For: Jun 16 April 30, 2026 6:35 AM - SEC Filing Form EFFECT Aprea Therapeutics, Inc. April 30, 2026 6:16 AM - SEC Filing Form 424B3 Aprea Therapeutics, Inc. April 29, 2026 5:17 PM - SEC Filing CatalYm names Christian Schade as board chairman April 28, 2026 7:00 AM - StreetInsider CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors April 28, 2026 7:00 AM - BizWire Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN April 27, 2026 8:09 AM - SEC Filing Full Article List